GeNeuro【GNRO】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.076

買値

0.0762

売値

0.086

出来高

248,615

0.076 日の範囲 0.10

0.0428 52 週間の範囲 2.35

時価総額

2.262M

前日終値

0.0898

始値

0.0808

時刻

1000

0.076

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

180,354

発行済株式数

29,760,933

配当利回り

PER

0.00

1 株当たり利益 (EPS)

歳入

純利益

-14.76M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.geneuro.com

本社

Geneva, Che

設立

GeNeuro SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker GNRO. The last closing price for GeNeuro was 0.09 €. Over the last year, GeNeuro shares have traded in a share price range of 0.0428 € to 2.35 €.

GeNeuro currently has 29,760,933 shares in issue. The market capitalisation of GeNeuro is 2.67 € million.

De nouvelles données soutenant une nouvelle approche de médecine de précision pour les patients atteints de SLA avec le GNK-301 de GeNeuro présentées lors du 35e Symposium international sur la SLA/MMN

Regulatory News: GeNeuro (Euronext Paris : CH0308403085 - GNRO), société biopharmaceutique dont l'objectif est de s'attaquer aux facteurs de progression des maladies neurodégénératives et...

GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva...

GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune...

GeNeuro annonce déposer une requête de sursis concordataire au Tribunal de première instance de Genève

Regulatory News: GeNeuro (Euronext Paris : CH0308403085 – GNRO), société biopharmaceutique développant de nouveaux traitements pour les maladies neurodégénératives et auto-immunes, telles que la...

GeNeuro : Fin du contrat de liquidité conclu avec GILBERT DUPONT

Regulatory News: La société GENEURO (Paris:GNRO) et la société GILBERT DUPONT ont mis fin au contrat de liquidité conclu le 06 mars 2021. Cette résiliation a pris effet le 30 juin 2024 au soir. A...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.023	-23.2323232323	0.099	0.113	0.0732	345044	0.08462874	DE
4	-0.0008	-1.04166666667	0.0768	0.228	0.0428	475220	0.1216947	DE
12	0.0004	0.529100529101	0.0756	0.228	0.0428	180354	0.11626489	DE
26	-1.584	-95.421686747	1.66	1.99	0.0428	136712	0.1308897	DE
52	-0.934	-92.4752475248	1.01	2.35	0.0428	74834	0.22452488	DE
156	-3.524	-97.8888888889	3.6	4.06	0.0428	28031	0.4459748	DE
260	-3.394	-97.8097982709	3.47	6.28	0.0428	20189	0.94008023	DE

GNRO - Frequently Asked Questions (FAQ)

What is the current GeNeuro share price?

The current share price of GeNeuro is 0.076 €

How many GeNeuro shares are in issue?

GeNeuro has 29,760,933 shares in issue

What is the market cap of GeNeuro?

The market capitalisation of GeNeuro is EUR 2.67M

What is the 1 year trading range for GeNeuro share price?

GeNeuro has traded in the range of 0.0428 € to 2.35 € during the past year

What is the reporting currency for GeNeuro?

GeNeuro reports financial results in EUR

What is the latest annual profit for GeNeuro?

The latest annual profit of GeNeuro is EUR -14.76M

What is the registered address of GeNeuro?

The registered address for GeNeuro is 18 CHEMIN DES AULX, PLAN-LES-OUATES, GENEVA, 1228

What is the GeNeuro website address?

The website address for GeNeuro is www.geneuro.com

Which industry sector does GeNeuro operate in?

GeNeuro operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
TMBSZTME Pharma NV	0.02 € (185.71%)	132.5k
MLGEQGentlemen S Equity SA	0.0175 € (118.75%)	1.14k
ALCYBCybergun	0.0002 € (100.00%)	17.54M
MLAAHAmatheon Agri Holding NV	0.0185 € (54.17%)	40.1k
ALARFAdeunis	0.94 € (28.77%)	5.27k
MLSMLSmalto	0.0125 € (-37.50%)	2.34k
MLFTIFrance Tourisme Immobilier	0.025 € (-35.90%)	56.77k
CNVCnova NV	0.209 € (-19.62%)	26.38k
MLWEAWeaccess Group	0.382 € (-16.96%)	5.95k
ALEUPEuroplasma	0.0353 € (-15.95%)	3.16M
ATOAtos SE	0.0021 € (0.00%)	2.71B
BCPBanco Comercial Portugues SA	0.4493 € (-0.69%)	66.54M
ALHGLouis Hachette Group	1.3342 € (4.87%)	52.04M
KPNKoninklijke KPN NV	3.509 € (-1.21%)	26.9M
VIVVivendi SE	2.51 € (2.41%)	26.39M

銘柄コード

株価

出来高

ATOAtos SE

0.0021 €

(0.00%)

2.71B

BCPBanco Comercial Portugues SA

0.4493 €

(-0.69%)

66.54M

ALHGLouis Hachette Group

1.3342 €

(4.87%)

52.04M

KPNKoninklijke KPN NV

3.509 €

(-1.21%)

26.9M

VIVVivendi SE

2.51 €

(2.41%)

26.39M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

GeNeuro SA (GNRO)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

GeNeuro SA について

GNRO 最新ニュース

De nouvelles données soutenant une nouvelle approche de médecine de précision pour les patients atteints de SLA avec le GNK-301 de GeNeuro présentées lors du 35e Symposium international sur la SLA/MMN

GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings

GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model

GeNeuro annonce déposer une requête de sursis concordataire au Tribunal de première instance de Genève

GeNeuro : Fin du contrat de liquidité conclu avec GILBERT DUPONT

New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND

GeNeuro SA obtient l’ouverture d’une procédure de sursis concordataire

GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model

GeNeuro annonce déposer une requête de sursis concordataire au Tribunal de première instance de Genève

GeNeuro : Fin du contrat de liquidité conclu avec GILBERT DUPONT

Geneuro SA : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Gilbert Dupont

GeNeuro Announces Results of the GNC-501 Study in Post-Covid-19 Syndrome

GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting

GNRO - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

GeNeuro SA (GNRO) 銘柄情報

GeNeuro SA (GNRO)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

GeNeuro SA について

GNRO 最新ニュース

GNRO - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手